- ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of SGN-B7H4V in Advanced Solid Tumors
Researchers are testing a new medicine called SGN-B7H4V for several advanced cancers, including certain breast, lung, and ovarian cancers. This early-stage study aims to find a safe dose and see what effects it has. It's for adults whose cancer has spread or come back.
France · Spain · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
This study is testing a new medicine, TRK-950, in adults with advanced cancers like bladder, bowel, stomach, and ovarian cancer. Researchers want to find the right dose, understand if it's safe, and see how well it works when given alongside other cancer treatments.
France - recruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
United States · France · Spain - recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
This study looks at a new drug, Mirvetuximab Soravtansine, for women with advanced ovarian, peritoneal, or fallopian tube cancer that has resisted previous treatments. It aims to see how safe and effective the drug is, especially for cancers with a specific protein.
United States · Australia · Belgium - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
United States · Argentina · Australia - active not recruitingPHASE2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
This study looks at a new drug, mirvetuximab soravtansine, with carboplatin for certain types of ovarian, primary peritoneal, or fallopian tube cancer. It's for people whose cancer has come back but responded well to previous platinum-based chemotherapy.
United States · Belgium · Canada